Free Trial
OTCMKTS:SSMXY

Sysmex 8/6/2025 Earnings Report

Sysmex logo
$12.83 -0.03 (-0.23%)
As of 09/4/2025 03:59 PM Eastern

Sysmex EPS Results

Actual EPS
$0.05
Consensus EPS
$0.12
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Sysmex Revenue Results

Actual Revenue
$717.09 million
Expected Revenue
$807.27 million
Beat/Miss
Missed by -$90.18 million
YoY Revenue Growth
N/A

Sysmex Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Sysmex's next earnings date is estimated for Wednesday, November 5, 2025, based on past reporting schedules.

Conference Call Resources

Sysmex Earnings Headlines

What's the Best Way to Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain retirement accounts. Without the right strategy, these withdrawals can significantly increase your tax bill and shrink your nest egg. SmartAsset outlines six strategies that could help reduce your RMDs and potentially lower your tax burden. Their free tool can match you with vetted fiduciary financial advisors in your area—professionals legally bound to act in your best interest.tc pixel
See More Sysmex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sysmex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sysmex and other key companies, straight to your email.

About Sysmex

Sysmex (OTCMKTS:SSMXY) Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis. In coagulation testing, Sysmex provides instruments and reagents to assess blood‐clotting function and monitor anticoagulant therapy. Its urine analyzers combine digital imaging with automated particle analysis, while immunochemistry systems enable quantitative measurement of biomarkers for infectious disease, hemostasis and diabetes monitoring.

Sysmex maintains a global footprint with regional headquarters and sales subsidiaries in North America, Europe, Asia‐Pacific, Latin America and Africa. Its products and services reach more than 150 countries, supported by local service networks that offer training, maintenance and technical support. The company collaborates with academic and industrial partners to develop molecular diagnostic assays and next‐generation testing platforms, positioning itself at the forefront of personalized medicine and digital health solutions.

Founded in 1968, Sysmex has grown through continuous investment in research and development. The company is led by President and Chief Executive Officer Yutaka Yamada, supported by an executive team focused on innovation, quality and international expansion. Over its history, Sysmex has earned a reputation for reliability and precision in clinical diagnostics, driving efforts to improve patient care and laboratory efficiency worldwide.

View Sysmex Profile

More Earnings Resources from MarketBeat